227 related articles for article (PubMed ID: 21806334)
1. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.
Christoph DC; Schuler M
Expert Rev Anticancer Ther; 2011 Jul; 11(7):1115-30. PubMed ID: 21806334
[TBL] [Abstract][Full Text] [Related]
2. Targeting Polo-like kinase in cancer therapy.
Degenhardt Y; Lampkin T
Clin Cancer Res; 2010 Jan; 16(2):384-9. PubMed ID: 20068088
[TBL] [Abstract][Full Text] [Related]
3. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
Schöffski P
Oncologist; 2009 Jun; 14(6):559-70. PubMed ID: 19474163
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
Chopra P; Sethi G; Dastidar SG; Ray A
Expert Opin Investig Drugs; 2010 Jan; 19(1):27-43. PubMed ID: 20001553
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC.
Medema RH; Lin CC; Yang JC
Clin Cancer Res; 2011 Oct; 17(20):6459-66. PubMed ID: 22003073
[TBL] [Abstract][Full Text] [Related]
6. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
[TBL] [Abstract][Full Text] [Related]
7. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
8. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
Ikezoe T; Yang J; Nishioka C; Takezaki Y; Tasaka T; Togitani K; Koeffler HP; Yokoyama A
Leukemia; 2009 Sep; 23(9):1564-76. PubMed ID: 19421227
[TBL] [Abstract][Full Text] [Related]
9. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chembiochem; 2009 May; 10(7):1145-8. PubMed ID: 19350612
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
[TBL] [Abstract][Full Text] [Related]
11. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells.
Grinshtein N; Datti A; Fujitani M; Uehling D; Prakesch M; Isaac M; Irwin MS; Wrana JL; Al-Awar R; Kaplan DR
Cancer Res; 2011 Feb; 71(4):1385-95. PubMed ID: 21303981
[TBL] [Abstract][Full Text] [Related]
12. Selectivity-determining residues in Plk1.
Kothe M; Kohls D; Low S; Coli R; Rennie GR; Feru F; Kuhn C; Ding YH
Chem Biol Drug Des; 2007 Dec; 70(6):540-6. PubMed ID: 18005335
[TBL] [Abstract][Full Text] [Related]
13. Getting in and out of mitosis with Polo-like kinase-1.
van Vugt MA; Medema RH
Oncogene; 2005 Apr; 24(17):2844-59. PubMed ID: 15838519
[TBL] [Abstract][Full Text] [Related]
14. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
15. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
Strebhardt K; Becker S; Matthess Y
Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
[TBL] [Abstract][Full Text] [Related]
16. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE
Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381
[TBL] [Abstract][Full Text] [Related]
17. BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1).
Wäsch R; Hasskarl J; Schnerch D; Lübbert M
Recent Results Cancer Res; 2010; 184():215-8. PubMed ID: 20072841
[TBL] [Abstract][Full Text] [Related]
18. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
Stewart HJ; Kishikova L; Powell FL; Wheatley SP; Chevassut TJ
Exp Hematol; 2011 Mar; 39(3):330-8. PubMed ID: 21184800
[TBL] [Abstract][Full Text] [Related]
19. PLK1 inhibitors: setting the mitotic death trap.
Plyte S; Musacchio A
Curr Biol; 2007 Apr; 17(8):R280-3. PubMed ID: 17437704
[TBL] [Abstract][Full Text] [Related]
20. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors.
Yim H
Anticancer Drugs; 2013 Nov; 24(10):999-1006. PubMed ID: 23949254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
